Change in WOMAC subscales* from baseline to week 6 and effect size for knee and hip for the naproxen and placebo treated groups
| WOMAC subscale | Pain | Stiffness | Physical function |
|---|---|---|---|
| *Values are mean (SD). | |||
| BL, baseline; CI, confidence interval; WOMAC, Western Ontario and McMaster Universities osteoarthritis index. | |||
| Knee (naproxen) | (n = 280) | (n = 279) | (n = 278) |
| BL | 44.2 (20.5) | 48.9 (24.1) | 47.1 (21.0) |
| BL-6 | −16.62 (20.50) | −19.39 (23.01) | −16.31 (17.89) |
| Effect size | 0.81 | 0.80 | 0.78 |
| Knee (placebo) | (n = 75) | (n = 75) | (n = 72) |
| BL | 45.11 (20.3) | 50.6 (25.9) | 48.2 (19.8) |
| BL-6 | −6.75 (19.12) | −9.33 (23.91) | −6.75 (18.05) |
| Effect size | 0.33 | 0.36 | 0.34 |
| Hip (naproxen) | (n = 123) | (n = 123) | (n = 123) |
| BL | 47.3 (22.2) | 49.3 (23.7) | 49.7 (22.9) |
| BL-6 | −12.33 (19.78) | −12.97 (21.52) | −11.66 (16.78) |
| Effect size | 0.56 | 0.55 | 0.51 |
| Hip (placebo) | (n = 33) | (n = 33) | (n = 33) |
| BL | 44.7 (20.1) | 48.6 (23.3) | 47.5 (21.8) |
| BL-6 | −3.24 (22.27) | −8.15 (20.88) | −4.35 (17.67) |
| Effect size | 0.16 | 0.35 | 0.20 |
| Difference response knee–hip (95% CI), naproxen | −4.66 (−8.83 to −0.50), p = 0.03 | −6.64 (−11.16 to −2.11), p = 0.004 | −4.77 (−9.82 to −0.90), p = 0.016 |
| Difference response knee–hip (95% CI), placebo | −2.89 (−11.37 to 5.59), p = 0.50 | −0.10 (−9.25 to 9.05), p = 0.98 | −2.29 (−9.82 to 5.24), p = 0.55 |